GCM
GMAB icon

Genus Capital Management’s Genmab GMAB Stock Holding History

Genus Capital Management’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,775
Closed -$380K – 264
2023
Q3 		$380K Sell
10,775
-340
-3% -$13K 0.06% 157
2023
Q2 		$422K Buy
+11,115
New +$443K 0.06% 167

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $374B AUM 17.66% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Genus Capital Management's GMAB Position: Q4 2023 in Review

Genus Capital Management sold out of Genmab (GMAB) in Q4 2023, closing a stake of 10,775 shares — an estimated $380K sold.

Genus Capital Management first reported a position in GMAB in Q2 2023 and held it in 2 quarters. The position peaked at $422K in Q2 2023. 225 funds tracked by Wall St. Rank hold GMAB as of Q4 2023.

  • Genus Capital Management reported no remaining Genmab position as of Q4 2023 after selling out during the quarter.
  • Genus Capital Management sold 10,775 Genmab shares in Q4 2023, an estimated $380K.
  • Genus Capital Management first reported a position in Genmab in Q2 2023 and held it in 2 quarters.
  • Genus Capital Management's Genmab position peaked at $422K in Q2 2023.
  • 225 funds tracked by Wall St. Rank held Genmab as of Q4 2023.

Based on Genus Capital Management's 13F filing for Q4 2023, filed 6 Feb 2024.